|
Post by dh4mizzou on May 18, 2021 10:05:30 GMT -5
Joey. I visit these threads because I am interested in ALL viewpoints. I do look forward to Peppy's take on the charts. I just don't take a lot of time looking at them.
|
|
|
Post by peppy on May 18, 2021 10:21:43 GMT -5
Ahhhh. I do put my whole heart into it, trying to point out what I see with circles and arrows. price seems to be going up on low volume at the moment. MNKD has started to follow the IBB. ? Not sure of what purpose or why that poster would make that statement as no one has to tap any thread if it gives them a headache 🤷♂️...btw, I find it also follows the XBI 😉 That you said that made me look the other day, that's when I saw the break out and then the test, which it seems to lifting from. I looked today, it is also following UTHR. MNKD the caboose. I was listening to TWIV yesterday and Richard after 3 months now, lit up again about the mRNA vaccines and the prospects of things to come with this technology. I wouldn't mind being the caboose on one of those trains. Antibodies are proteins. MNKD UTHR
|
|
|
Post by mytakeonit on May 18, 2021 13:54:19 GMT -5
The only thing I know ... is that I have more shares than Goldman Sachs !!!
But, that's mytakeonit
|
|
|
Post by peppy on May 18, 2021 15:04:36 GMT -5
MNKD Nasdaq real time volume, 1,318,723 shares. MNKD Nasdaq summary volume, 2,107,476 Avg. Volume 5,266,532
4.26. +0.03 (+0.71%) At close: 4:00PM EDT
16:05:09 $4.3167. 227,795 shares. 16:00:02 $4.26 13 16:00:02 $4.26 11,157 16:00:02 $4.26 414 16:00:01 $4.26 3,846
|
|
|
Post by peppy on May 19, 2021 6:20:46 GMT -5
MNKD Nasdaq real time volume, 1,318,723 shares. MNKD Nasdaq summary volume, 2,107,476 Avg. Volume 5,266,532 4.26. +0.03 (+0.71%) At close: 4:00PM EDT 16:05:09 $4.3167. 227,795 shares. 16:00:02 $4.26 13 16:00:02 $4.26 11,157 16:00:02 $4.26 414 16:00:01 $4.26 3,846 The real time shares traded yesterday now saids, 2,358,719, which is once again greater than summary volume, MNKD is being bought.
|
|
|
Post by peppy on May 19, 2021 16:19:47 GMT -5
MNKD nasdaq real time volume, 1,571,838 shares. MNKD Nasdaq summary volume, 2,219,732 shares. Avg. Volume 5,255,822
$4.23. -0.03 (-0.70%) At close: 4:00PM EDT
|
|
|
Post by peppy on May 20, 2021 5:23:11 GMT -5
MNKD nasdaq real time volume, 1,571,838 shares. MNKD Nasdaq summary volume, 2,219,732 shares. Avg. Volume 5,255,822 $4.23. -0.03 (-0.70%) At close: 4:00PM EDT real time shares traded yesterday changed. 2,219,896, the new number. In 5 years time, I have never seen MNKD trade like this. This has been going on for months. 2 to 3 months. for years, no pre market trades, no post market trades.
|
|
|
Post by peppy on May 20, 2021 16:04:43 GMT -5
MNKD Nasdaq real time volume, 1,531,066 shares. MNKD Nasdaq summary volume, 2,025,712 shares. Avg. Volume 5,154,079
$4.31. +0.08 ( +1.8913%) At close: 4:00PM EDT
|
|
|
Post by peppy on May 21, 2021 6:02:29 GMT -5
MNKD Nasdaq real time volume, 1,531,066 shares. MNKD Nasdaq summary volume, 2,025,712 shares. Avg. Volume 5,154,079 $4.31. +0.08 ( +1.8913%) At close: 4:00PM EDT new number of real time shares traded yesterday. 2,044,556
|
|
|
Post by Clement on May 21, 2021 10:29:15 GMT -5
Puts at 4.50 strike price expire today. I mention this because of the large open interest -- 8781 contracts representing 878,100 underlying shares. The buyers of those puts would like the share price to stay under 4.50.
|
|
|
Post by castlerockchris on May 21, 2021 12:02:41 GMT -5
Puts at 4.50 strike price expire today. I mention this because of the large open interest -- 8781 contracts representing 878,100 underlying shares. The buyers of those puts would like the share price to stay under 4.50. Completely happy to see these expire worthless as I am on the short side of that trade and plan to turn around and repeat it on Monday if the price is write! See what I did there? Write - cracking myself up on a Friday!
|
|
|
Post by peppy on May 21, 2021 15:06:03 GMT -5
MNKD nasdaq real time volume, 1,374,791 shares. MNKD Nasdaq summary volume, 2,025,051 shares. Avg. Volume 5,104,720
$4.24. -0.07 (-1.62%) At close: 4:00PM EDT
|
|
|
Post by peppy on May 22, 2021 8:07:07 GMT -5
MANNKIND Annual stock holders meeting. events.q4inc.com/vsm/MNKD/2021Number of shares out standing. 249,072,677 shares of company stock out standing on the record date. (so back to the pre reverse split number of shares.) 248 million of convertible debt. Debt 355 million. tyvasso approval December. UTHR royalties first half 2022. Afrezza trial, 10 to 12 million dollars. India trials enrolling during covid. UTHR revenue sources, 1. royalties. double digit royalties when approved and sold double digit net royalties on sales. 2. Income on manufactured product, manufacturing agreement to be completed shortly. looking at product cost plus type of arrangement. What was different, Mike said they have 3 or 4 or lots of formulation deals coming in. When have we heard that? Doing development deals. Mike sounds positive. some energy. Tyvaso success the focus. COPD a possible market is huge. and inhaled can not be disputed. Afrezza requires a new insulin category by the AMA to be ultra rapid. No vaccine manufacture has come to MNKD looking to produce a technosphere vaccine. Weekly chart, inside week. investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-announces-proposed-private-placementgeomean check in once and a while. I know you are busy managing your market short.
|
|
|
Post by gamblerjag on May 22, 2021 10:20:31 GMT -5
MANNKIND Annual stock holders meeting. events.q4inc.com/vsm/MNKD/2021Number of shares out standing. 249,072,677 shares of company stock out standing on the record date. (so back to the pre reverse split number of shares.) 248 million of convertible debt. Debt 355 million. tyvasso approval December. UTHR royalties first half 2022. Afrezza trial, 10 to 12 million dollars. India trials enrolling during covid. UTHR revenue sources, 1. royalties. double digit royalties when approved and sold double digit net royalties on sales. 2. Income on manufactured product, manufacturing agreement to be completed shortly. looking at product cost plus type of arrangement. What was different, Mike said they have 3 or 4 or lots of formulation deals coming in. When have we heard that? Doing development deals. Mike sounds positive. some energy. Tyvaso success the focus. COPD a possible market is huge. and inhaled can not be disputed. Afrezza requires a new insulin category by the AMA to be ultra rapid. No vaccine manufacture has come to MNKD looking to produce a technosphere vaccine. Weekly chart, inside week. investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-announces-proposed-private-placementgeomean check in once and a while. I know you are busy managing your market short. . I do believe that pre-split outstanding shares were up to 470,000,000 (give or take)
|
|
|
Post by peppy on May 22, 2021 13:02:38 GMT -5
g thank you. thank goodness.
|
|